Fig. 1: Breast cancer bone metastases is Mstn-positive and located in the osteoclast-bone-tumor interface. | Oncogene

Fig. 1: Breast cancer bone metastases is Mstn-positive and located in the osteoclast-bone-tumor interface.

From: Pharmacological inhibition of myostatin effectively ameliorates osteolytic lesions in syngeneic and xenograft breast cancer mouse models

Fig. 1: Breast cancer bone metastases is Mstn-positive and located in the osteoclast-bone-tumor interface.

A, B Mstn expression was analyzed in breast cancer bone metastasis from 27 patients. Sections were scored for Mstn expression score 1 = low, score 2 = moderate, score 3 = high. C Proportion of low, moderate and high myostatin-positive tissue samples is shown for luminal A-like (lumA-like), luminal B-like (lumB-like), and triple-negative and all subtypes. Luminal A-like, n = 9; luminal B-like, n = 11 and triple-negative, n = 7; All, n = 27; All data are mean ± SD, one-way ANOVA, Kruskal-Wallis test with multiple comparisons, *p ≤ 0.05, **p ≤ 0.01. D–G Human iliac crest biopsy sections of bone metastases from TNBC patients (n = 7). D H&E-overview staining (E) TRAP+ osteoclasts and (C) Mstn expression (brown) (G) Negative control:IgG. B = bone, TC = tumor cells, arrowheads = osteoclasts.

Back to article page